User:Mr. Ibrahem/Dinutuximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | GD2 |
| Clinical data | |
| Trade names | Unituxin, Isquette, Qarziba, others |
| Synonyms | Dinutuximab beta, Ch14.18, APN-311 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615022 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6422H9982N1722O2008S48 |
| Molar mass | 144,981.42 g·mol−1 |
Dinutuximab, sold under the trade name Unituxin among others, is a medication used to treat neuroblastoma.[6] It is used for children at high-risk who are still having problems despite other treatments.[3] It is given by injection into a vein.[6]
Common side effects include pain, fever, infusion reaction, low platelets, low white blood cells, low potassium, capillary leak syndrome, and liver problems.[5] Other side effects may include reversible posterior leukoencephalopathy syndrome, transverse myelitis, eye problems, and infection.[5] Use in pregnancy may harm the baby.[5] It is a monoclonal antibody that attaches to GD2, commonly found on neuroblastoma cells.[3] This binding causes the body's immune system to destroy them.[3]
Dinutuximab was approved for medical use in the United States in 2015.[6] While it was also approved in Europe in 2015, it was subsequently withdrawn in 2017.[7] Dinutuximab beta; however, received approval in Europe in 2017.[3] In the United States 17.5 mg costs about 14,000 USD as of 2021.[8]
References
[change | change source]- ↑ 1.0 1.1 "Qarziba Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 11 April 2020. Archived from the original on 28 August 2021. Retrieved 16 August 2020.
- ↑ "Dinutuximab (Unituxin) Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 23 January 2021. Retrieved 16 August 2020.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Qarziba EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 30 December 2020. Retrieved 16 August 2020.
- ↑ "Qarziba (Dinutuximab beta) 4.5 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 27 November 2019. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
- ↑ 5.0 5.1 5.2 5.3 5.4 "Unituxin- dinutuximab injection". DailyMed. 19 April 2019. Archived from the original on 4 August 2020. Retrieved 16 August 2020.
- ↑ 6.0 6.1 6.2 6.3 "Dinutuximab Monograph for Professionals". Drugs.com. Archived from the original on 13 September 2021. Retrieved 26 December 2021.
- ↑ "Unituxin EPAR". European Medicines Agency (EMA). Archived from the original on 14 August 2020. Retrieved 16 August 2020.
- ↑ "Unituxin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 26 December 2021.